Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line

Abstract

Recent findings suggest that DNA alkylating agents trigger cellular responses that overlap those activated after ionizing radiation. Moreover, activation of these responses is dependent upon a functional mismatch repair (MMR) system. These developments led us to test if MMR-deficient cells may be compromised in their ability to activate appropriate cellular signaling pathways after ionizing radiation. An initial experiment to address this notion was to determine the level of radiosensitivity of several MMR-deficient cell lines derived from patients with Hereditary Non-Polyposis Colorectal Cancer (HNPCC). While two of the three HNPCC lines investigated show levels of radiosensitivity consistent with that displayed by normal human fibroblasts, HCT-116 cells display moderate radiosensitivity compared to the other MMR-deficient lines. This increased sensitivity to ionizing radiation correlates with lowered levels of ATM expression in HCT-116. Analysis of genomic DNA from HCT-116 cells determined that these cells possess aberrant methylation of multiple CpG dinucleotides within the proximal promoter region of the ATM gene. The significance of this finding is underscored by our observations that co-culturing HCT-116 cells with the DNA demethylating agent 5-azacytidine reverses promoter methylation, promotes normal levels of ATM expression, and restores normal radiosensitivity. The proximal ATM promoter is a 520 bp region shared with the NPAT gene, and current evidence suggests that this region functions as a bi-directional promoter. We found that, unlike ATM, the methylation status of this intergenic region does not effect the expression of the NPAT gene. In sum, these observations indicate that the ATM gene is a novel target for epigentic silencing through inappropriate methylation of its proximal promoter region.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Athma P, Rappaport R, Swift M . 1996 Cancer Genet. Cytogenet. 92: 130–134

  • Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, Shiloh Y, Crawley JN, Reid T, Tagle D, Wynshaw-Boris A . 1996 Cell 86: 159–171

  • Barlow C, Ribaut-Barassin C, Zwingman TA, Pope AJ, Brown KD, Owens JW, Larson D, Harringtion EA, Haeberle AM, Mariani J, Eckhaus M, Herrup K, Bailly Y, Wynshaw-Boris A . 2000 Proc. Natl. Acad. Sci. USA 97: 871–876

  • Baylin SB, Belinsky SA, Herman JG . 2000 J. Natl. Cancer Inst. 92: 1460–1461

  • Bigbee WL, Langlois RG, Swift M, Jensen RH . 1989 Am. J. Hum. Genet. 44: 402–408

  • Bird A . 1992 Cell 70: 5–8

  • Brown KD, Barlow C, Wynshaw-Boris A . 1999 Am. J. Hum. Genet. 64: 46–50

  • Brown KD, Coulson RMR, Yen TJ, Cleveland DW . 1994 J. Cell Biol. 125: 1303–1312

  • Brown KD, Lataxes T, Kumar S, Mannino JL, Giardina J, Chen J, Baskaran R . 2000 J. Biol. Chem. 275: 6651–6656

  • Byrd PJ, Cooper PR, Stankovic T, Kullar HS, Watts GD, Robinson PJ, Taylor MR . 1996 Hum. Mol. Genet. 5: 1785–1791

  • Chen PC, Lavin MF, Kidson C, Moss D . 1978 Nature 274: 484–486

  • Chen X, Yang L, Udar N, Liang T, Uhrhammer N, Xu S, Bay JO, Wang Z, Dandakar S, Chiplunkar S, Klisak I, Telatar M, Yang H, Concannon P, Gatti RA . 1997 Mamm. Genome 8: 129–133

  • Costello JF, Berger MS, Huang HS, Cavenee WK . 1996 Cancer Res. 56: 2405–2410

  • Dork T, Bendix R, Bremer M, Rades D, Klopper K, Nicke M, Skawran B, Hector A, Yamini P, Steinmann D, Weise S, Stuhrmann M, Karstens JH . 2001 Cancer Res. 61: 7608–7615

  • Duckett DR, Bronstein SM, Taya Y, Modrich P . 1999 Proc. Natl. Acad. Sci. USA 96: 12384–12388

  • Ejima Y, Yang L, Sasaki MS . 2000 Int. J. Cancer 86: 262–268

  • Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG . 2000 J. Natl. Cancer Inst. 92: 564–569

  • Fearon ER, Vogelstein B . 1990 Cell 61: 759–767

  • Fritzell JA, Narayanan L, Baker SM, Bronner CE, Andrew SE, Prolla TA, Bradley A, Jirik FR, Liskay RM, Glazer PM . 1997 Cancer Res. 57: 5143–5147

  • Gatti RA, Tward A, Concannon P . 1999 Mol. Genet. Metab. 68: 419–423

  • Gnarra JR . 1998 J. Natl. Cancer Inst. 90: 1685–1687

  • Herman JG, Baylin SB . 2000 Curr. Top. Microbiol. Immunol. 249: 35–54

  • Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, Baylin SB . 1994 Proc. Natl. Acad. Sci. USA 91: 9700–9704

  • Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB . 1998 Proc. Natl. Acad. Sci. USA 95: 6870–6875

  • Hickman MJ, Samson LD . 1999 Proc. Natl. Acad. Sci. USA 96: 10764–10769

  • Hiraguri S, Godfrey T, Nakamura H, Graff J, Collins C, Shayesteh L, Doggett N, Johnson K, Wheelock M, Herman J, Baylin S, Pinkel D, Gray J . 1998 Cancer Res. 58: 1972–1977

  • Imai T, Yamauchi M, Seki N, Sugawara T, Saito T, Matsuda Y, Ito H, Nagase T, Nomura N, Hori T . 1996 Genome Res. 6: 439–447

  • Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R . 1997 Cancer Res. 57: 808–811

  • Kastan MB, Lim DS . 2000 Nat. Rev. Mol. Cell Biol. 1: 179–186

  • Khanna KK . 2000 J. Natl. Cancer Inst. 92: 795–802

  • Kinzler KW, Vogelstein B . 1996 Cell 87: 159–170

  • Knudson Jr AG . 1971 Proc. Natl. Acad. Sci. USA 68: 820–823

  • Lengauer C, Kinzler KW, Vogelstein B . 1997 Proc. Natl. Acad. Sci. USA 94: 2545–2550

  • Ma T, Van Tine BA, Wei Y, Garrett MD, Nelson D, Adams PD, Wang J, Qin J, Chow LT, Harper JW . 2000 Genes Dev. 14: 2298–2313

  • Morrell D, Cromartie E, Swift M . 1986 J. Natl. Cancer Inst. 77: 89–92

  • Nowell PC . 1976 Science 194: 23–28

  • Pandita TK, Hittelman WN . 1994 Mutat. Res. 310: 1–13

  • Rotman G, Shiloh Y . 1998 Hum. Mol. Genet. 7: 1555–1563

  • Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, Ashkenazi M, Pecker I, Frydman M, Harnik R, Patanjali SR, Simmons A, Clines GA, Sarteil A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers NGJ, Taylor AMR, Arlett CF, Miki T, Weissman SM, Lovett M, Collins FS, Shiloh Y . 1995 Science 268: 1749–1753

  • Swift M, Reitnauer PJ, Morrell D, Chase CL . 1987 N. Engl. J. Med. 316: 1289–1294

  • Taylor AM, Metcalfe JA, Thick J, Mak YF . 1996 Blood 87: 423–438

  • Teraoka SN, Malone KE, Doody DR, Suter NM, Ostrander EA, Daling JR, Concannon P . 2001 Cancer 92: 479–487

  • Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP . 1999 Proc. Natl. Acad. Sci. USA 96: 8681–8686

  • Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD, Markowitz SD . 1998 Proc. Natl. Acad. Sci. USA 95: 8698–8702

  • Xu Y . 1999 Adv. Immunol. 72: 179–189

  • Yan T, Schupp JE, Hwang HS, Wagner MW, Berry SE, Strickfaden S, Veigl ML, Sedwick WD, Boothman DA, Kinsella TJ . 2001 Cancer Res. 61: 8290–8297

  • Zhao J, Dynlacht B, Imai T, Hori T, Harlow W . 1998 Genes Dev. 12: 456–461

  • Ziv Y, Bar-Shira A, Pecker I, Russell P, Jorgensen TJ, Tsarfati I, Shiloh Y . 1997 Oncogene 15: 159–167

Download references

Acknowledgements

We thank Dr Bryan Gebhardt (Department of Ophthamology, LSUHSC) for allowing us access to the 137Cs irradiator, Dr Timothy Jorgensen (Georgetown University) for advice in conducting radiosensitivity analyses, and Dr Wade Harper (Baylor College of Medicine) for his generous gift of anti-NPAT antisera. This work was supported by a research project grant (RPG) from the American Cancer Society (GMC-98564), and a grant from the Louisiana Board of Regents Health Excellence Fund.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kevin D Brown.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, Wj., Vo, Q., Shrivastav, M. et al. Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line. Oncogene 21, 3864–3871 (2002). https://doi.org/10.1038/sj.onc.1205485

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205485

Keywords

This article is cited by

Search

Quick links